# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Revelation Biosciences reveals positive safety and biomarker data from its Phase 1 study (RVL-HV02) of Gemini. The study met it...
-Gemini administration induced statistically significant, dose dependent changes in key biomarkers of activity--Gemini was safe...
Revelation Biosciences (NASDAQ:REVB) reported quarterly losses of $(2.46) per share which missed the analyst consensus estimate...
Revelation Biosciences (NASDAQ:REVB) reported quarterly losses of $(8.33) per share which beat the analyst consensus estimate o...
Gemini is the company's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) for systemic administration....